References
- Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers): emergency use authorization (EUA) of the Pfizer BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19); 2021;1(12):2021 Available from: https://www.fda.gov/media/144413/download
- Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers): emergency use authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19); 2021 1 12 2021. Available from: https://www.fda.gov/media/144637/download
- Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers) emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19); 2021 1 12 2021. Available from: https://www.fda.gov/media/146304/download
- Shimabukuro TT, Nguyen M, Martin D, et al. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015;33:4398–4405.
- Vsafe after vaccination health checker 1 12 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html
- Centers for Disease Control and Prevention. V-safe COVID-19 vaccine pregnancy registry 1 12 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafepregnancyregistry.html
- McNeil MM, Gee J, Weintraub ES, et al. The vaccine safety datalink: successes and challenges monitoring vaccine safety. Vaccine. 2014;32:5390–5398.
- Centers for Disease Control and Prevention. Vaccine safety monitoring 1 12 2021. Available from: https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/index.html
- Rapid Cycle Analysis (RCA) to monitor the safety of COVID-19 vaccines in near real-time within the vaccine safety datalink 1 12 2021. Available from: https://www.cdc.gov/vaccinesafety/pdf/VSD-1342-COVID19-RCA-Protocol_FinalV1.1_508.pdf.
- Klein N. Rapid cycle analysis to monitor the safety of COVID-19 vaccines in near real-time within the vaccine safety datalink: myocarditis and anaphylaxis 1 12 2021. Available form: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-08-30/04-COVID-Klein-508.pdf
- Gee J, Marquez P, Su J, et al. First month of COVID-19 vaccine safety monitoring – United States, December 14, 2020–January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:283–288.
- Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons. N Engl J Med. 2021 Apr 21:NEJMoa2104983. DOI:https://doi.org/10.1056/NEJMoa2104983. Epub ahead of print. PMID: 33882218; PMCID: PMC8117969. •• Of considerable importance: the first post-authorization safety data published on mRNA COVID-19 vaccines in pregnant persons.
- Olson C. COVID-19 vaccine safety in pregnancy: updates from the v-safe COVID-19 vaccine pregnancy registry 1 12 2021. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-09-22/09-COVID-Olson-508.pdf
- Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US – December 14, 2020-January 18, 2021. JAMA. 2021;325(11):1101–1102.
- Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States 1 12 2021. Available from: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html
- See I, Su JR, Lale A, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA. 2021;325(24):2448–2456.
- MacNeil JR, Su JR, Broder KR, et al. Updated recommendations from the advisory committee on immunization practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients – United States, April 2021. MMWR Morb Mortal Wkly Rep. 2021;70:651–656.
- Centers for Disease Control and Prevention. Clinical care considerations for COVID-19 vaccination 1 12 2021. Available from: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/index.html
- Advisory Committee on Immunization Practices (ACIP). COVID-19 vaccine safety updates, June 23, 2021. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/03-COVID-Shimabukuro-508.pdf
- Centers for Disease Control and Prevention. Clinical considerations: myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines among adolescents and young adults 1 12 2021. Available from: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html
- Food and Drug Administration. Coronavirus (COVID-19) Update: June 25, 2021. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-june-25-2021
- Advisory Committee on Immunization Practices (ACIP). Guillain-Barré syndrome (GBS) after Janssen COVID-19 vaccine: Vaccine Adverse Event Reporting System (VAERS); [ cited 2021 Jul 22]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-07/02-COVID-Alimchandani-508.pdf
- Advisory Committee on Immunization Practices (ACIP). Rapid Cycle Analysis (RCA) to monitor the safety of COVID-19 vaccines in near real-time within the vaccine safety datalink: Guillain-Barré syndrome (GBS); [ cited 2021 Jul 22]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-07/03-COVID-Klein-508.pdf